- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
The Board of Solara Active Pharma Sciences has approved the unaudited financial results for the quarter and nine months ended December 31, 2024. The key highlights include a revenue of ₹3,018 crore, up 21% year-over-year, with EBITDA margins improving to 19.6%. Significant decisions from the meeting also include the in-principle approval to explore a demerger of the CRAMS and Polymers business into a separate entity, aimed at enabling enhanced focus and growth potential for both segments. Management will initiate preparatory steps for this strategic move.
All announcements from Solara Active Pharma Sciences Limited